PT  - JOURNAL ARTICLE
AU  - Erica Lasek-Nesselquist
AU  - Janice Pata
AU  - Erasmus Schneider
AU  - Kirsten St. George
TI  - A tale of three SARS-CoV-2 variants with independently acquired P681H mutations in New York State
AID  - 10.1101/2021.03.10.21253285
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.10.21253285
4099  - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21253285.short
4100  - http://medrxiv.org/content/early/2021/03/12/2021.03.10.21253285.full
AB  - Several SARS-CoV-2 variants of concern have independently acquired some of the same Spike protein mutations - notably E484K, N501Y, S477N, and K417T - associated with increased viral transmission and/or reduced sensitivity to neutralization by antibodies. Repeated evolution of the same mutations, particularly in variants that are now rapidly spreading in various regions of the world, suggests a fitness advantage. Mutations at position P681 in Spike – possibly affecting viral transmission - have also evolved multiple times, including in two variants of concern. Here, we describe three variants circulating in New York State that have independently acquired a P681H mutation and the different trajectories they have taken. While one variant rose to high prevalence since later summer 2020 it appears to be in decline. The other two variants were more recently detected in New York and harbor additional Spike mutations that might be cause for continued monitoring. The latter two P681H variants have shown moderate increases in prevalence but ultimately all might be subject to the same fate as more competitive variants come to dominate the scene.Competing Interest StatementThe authors have declared no competing interest.Funding StatementInitial funding for sequencing was generously provided by the New York Community Trust. This publication was also supported by Cooperative Agreement number NU50CK000516, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the New York State Department of Health Institutional Review Board, under study numbers 02-054 and 07-022.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll SARS CoV-2 genomes are available on GISAID.org